Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | LEPRE1 |
| Gene Name: | LEPRE1 |
| Protein Full Name: | Prolyl 3-hydroxylase 1 |
| Alias: | Leucine- and proline-enriched proteoglycan 1 |
| Mass (Da): | 83376 |
| Number AA: | 736 |
| UniProt ID: | Q32P28 |
| Locus ID: | 6417 |
| COSMIC ID: | LEPRE1 |
| Gene location on chromosome: | Location: |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.68 |
| Normal role description: | LEPRE1is an extracellular matrix protein as a basement membrane-associated chondroitin sulfate proteoglycan (CSPG) and it acts as a enzyme of the collagen prolyl hydroxylase family. It is required for correct collagen synthesis and assembly. It also has growth suppressive activity in fibroblasts. Mutations in this gene are associated with ovarian cancer. |
| Commentary on involvement of protein in cancer: | Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts. |